Utility of a predictive model for chronic kidney disease in level 1 medical care.

disease-associated genetic variants in the complement alternative pathway. Biochim Biophys Acta. 2011;1812:12–22. 5. George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park). 2011;25:908–14. 6. Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, et al. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrologia. 2013;33:27–45 [Article in English, Spanish]. 7. Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist. 2007;12:11–9. 8. Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, et al. Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol. 1989;7:781–9. 9. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: Clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012;91:195–205. 10. Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy: Eculizumab for atypical haemolytic uraemic syndrome: What next? Nat Rev Nephrol. 2013;9:495–6. Maria Rullana, Joaquín Manriqueb,∗, Loreto Fernandez Lorenteb, Diana Izquierdob, Fernanda Slonb y Antonio José Rullan c